Abstract
Proteinaceous meningococcal B vaccines are under development, and the most advanced, Bexsero, is currently being evaluated by the European Medicines Agency. Approval, if granted, will be based on safety, immunogenicity, and theoretical strain coverage established in vitro. Clinical effectiveness will only be determined after market release. New, more effective influenza vaccines are also being developed. A trivalent attenuated nasal influenza vaccine (Fluenz) shows better efficacy in children than the classic trivalent seasonal inactivated vaccine, but its use is restricted to children over 2 years of age because of safety and efficacy considerations. The more potent trivalent (MF59) adjuvated inactivated influenza vaccine (Fluad), licensed for adults over 65 years of age, is being evaluated through a pediatric investigation plan. This vaccine could be useful for infants in whom unadjuvated inactivated vaccines are poorly protective, but its safety must first be fully established.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
